Drug intelligence / Profile preview

NFS-09

Development stage: Preclinical
Lead developer: Neurophth
Modality: AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration: Ophthalmic

Overview

NFS-09 is an investigational gene therapy candidate being developed by Neurophth (also known as Wuhan Kaidejinuo Biotechnology). The drug utilizes a recombinant adeno-associated virus (AAV) vector to deliver therapeutic genetic material to the eye. While Neurophth has a robust pipeline of treatments for inherited retinal diseases such as Leber hereditary optic neuropathy (LHON) and autosomal dominant optic atrophy (DOA), the specific genetic target and primary indication for NFS-09 have not yet been publicly disclosed. The program is currently in the preclinical stage of development, focusing on addressing unmet needs in the field of ophthalmology through genetic intervention.

Beyond the preview

Go deeper on NFS-09.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NFS-09.

Explore the full profile